MedTrace Logo

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

NCT05462990 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2026-03-31

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to find out if the investigational treatment named QUC398 had beneficial effects on osteoarthritis (OA) knee pain and knee cartilage, and if it was safe and tolerated.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

QUC398

QUC398 150 mg/mL, solution for subcutaneous (s.c) injection (1 mL). 2 injections were administered to complete 300 mg.

DRUG

Placebo

Matching Placebo solution for s.c. injection (1 mL). 2 injections were administered per dose to ensure blinding.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2024-08-02
Completion
2025-04-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Denmark
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462990 on ClinicalTrials.gov